ANVS
Annovis Bio·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ANVS
Annovis Bio, Inc.
A clinical-stage biotech company developing novel treatments for neurodegenerative diseases using its proprietary peptide-based technology
101 Lindenwood Drive, Suite 225, Malvern, PA 19355
--
Annovis Bio, Inc., was incorporated under the laws of the State of Delaware on April 29, 2008. Annovis is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of Parkinson's disease (" PD ") and Alzheimer's disease (" AD ") and neurodegenerative diseases. The company's lead compound, ANVS-401, is a neurochemical nerve defect therapy that inhibits neurodegeneration and inhibits the conversion of neurotoxic proteins into adults and normalized axonal vesicle transport.
Company Financials
EPS
ANVS has released its 2025 Q3 earnings. EPS was reported at -0.37, versus the expected -0.37, meeting expectations. The chart below visualizes how ANVS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
